Overview

Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention

Status:
NOT_YET_RECRUITING

Trial end date:
2030-06-01

Target enrollment:

Participant gender:

Summary

The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones. Study interventions: * Empagliflozin 25 mg once daily per os for 36 months * Personalized dietary counseling for 36 months. Control interventions: * Placebo once daily per os for 36 months * Generic dietary counseling for 36 months.

Phase:

PHASE3

Details

Lead Sponsor:

Insel Gruppe AG, University Hospital Bern

Treatments:

empagliflozin